anti-FN14 CAR-T cells

Anti-FN14 CAR-T cells are an experimental second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target Fibroblast Growth Factor-Inducible 14 (FN14), also known as the TWEAK receptor (TNFRSF12A). FN14 is a member of the TNF receptor superfamily that is selectively overexpressed in several treatment-refractory solid tumors, including clear cell renal cell carcinoma (ccRCC), metastatic castration-resistant prostate cancer (mCRPC), and glioblastoma (GBM), while maintaining low expression in normal tissues. The CAR construct typically incorporates either CD28 or 4-1BB costimulatory domains alongside CD3ζ signaling. Research indicates that the efficacy of these CAR-T cells can be significantly enhanced when combined with methylseleninic acid (MSA), a metabolite of seleno-L-methionine. MSA acts by suppressing tumor-derived immunosuppressive factors such as TGF-β1 and PD-L1 and directly improving the metabolic fitness and sustained effector function of the CAR-T cells, thereby addressing common challenges of exhaustion in the solid tumor microenvironment.

Other names

FN14-targeted CAR-T cellsFN-14-targeted CAR-T cellsFN 14-targeted CAR-T cellsanti-TNFRSF12A CAR-T cellsanti-TNFRSF-12A CAR-T cellsanti-TNFRSF 12A CAR-T cellsTWEAK receptor-targeted CAR-T cells